fda glp-1 safety warning september 2025 Pipeline Update: August - Prime Therapeutics What Patients Need to Know

Along with kidney injury, more significant concerns with GLP-1 receptor agonists may also include diabetic retinopathy, thyroid tumors or allergic reactions

The findings are not surprising, but they help to answer an important, unanswered question about GLP-1 drugs and sexual health

Over six years, they identified approximately 100 cases annually, noting the highest risk within the first year of medication use

But Eimer emphasized that the findings should not discourage appropriate use of GLP-1 drugs, which have become increasingly popular for treating diabetes, obesity, cardiovascular disease and sleep apnea

Patients with documented pancreatic insufficiency or ongoing pain may face higher contraindication risk